Neuroendocrine Tumor

She was initially managed conservatively with stress-dose hydrocortisone and low-dose cabergoline under close clinical and visual monitoring...Postoperatively, she developed cerebrospinal fluid rhinorrhea that resolved with lumbar drainage, as well as transient diabetes insipidus treated with desmopressin...In hemorrhagic sellar lesions, markedly elevated prolactin may reflect either a prolactinoma or stalk effect; a rapid postoperative prolactin decline supports stalk compression as the dominant mechanism. Close observation during conservative management is essential, and clinical deterioration should prompt timely surgical decompression to optimize neurological and endocrine outcomes.

Furthermore, clonal evolution analysis revealed that the two tumor components shared a set of 160 identical somatic mutations (accounting for approximately 16% of the total mutations in each component). This study delineates a dynamic evolutionary process within the pulmonary neuroendocrine tumor spectrum, confirming that a subset of atypical carcinoids can progress to small cell lung carcinoma through a transformation pathway.

Due to its rarity, PACC remains a diagnostic challenge. It has a better prognosis than PDAC; radical resection is recommended.

Current evidence suggests that AFP identifies biologically aggressive subsets of GEP-NENs, reflecting disease burden in specific contexts. While AFP should not be considered an independent biomarker, it holds potential as a contextual signal of aggressive tumor biology and as an adjunctive tool within integrated clinical and pathological frameworks.

A 68Ga-DOTANOC PET/CT scan revealed a somatostatin receptor-expressing mass in the pancreas. Surgical resection confirmed a grade 2 pancreatic NET consistent with glucagonoma, emphasizing that normal glucagon levels do not rule out glucagonoma and highlighting the utility of SSTR PET/CT in diagnosis.

The SPR‑POF platform demonstrated portability, cost-effectiveness (estimated 5 USD/unit), and operational simplicity, highlighting its potential for point-of-care testing (POCT) applications. Although limited by small patient numbers, these findings support MAVS as a promising predictive biomarker in SCLC, warranting validation in larger prospective studies.

This study explores ARX, PDX1, and serotonin expression in pancreatic neuroendocrine tumors with sclerosing morphology. Most neuroendocrine tumors with this morphologic pattern displayed either an α-cell (ARX predominant expression) or β-cell (PDX1 predominant expression) phenotype. Serotonin expression was associated with a β-cell phenotype and more indolent behavior.

This FAERS analysis characterizes agent-specific safety profiles, informing pharmacovigilance strategies. Mechanistic profiling of adverse drug reactions optimizes evidence-based treatment, enhancing medication safety and refining benefit-risk profiles in clinical practice.

Treatment with D1 LND is recommended for gastric neuroendocrine carcinoma (g-NEC), g-NET with lymphadenopathy, and grade 3 disease. Lymphadenectomy generally is unnecessary for g-GIST, except for those with persistent lymphadenopathy after neoadjuvant therapy or uncommon mutations.

Genetic testing identified a pathogenic VHL mutation: NM_000551.4(VHL):c.508G>A, consistent with VHL type 2C phenotype. Systematic screening for other VHL-associated lesions was negative. This case highlights the diagnostic challenge posed by clinically silent pheochromocytomas and underscores the importance of genetic evaluation in atypical adrenal tumors.

Further optimization is required to improve their long-term proliferation and differentiation potential. Together, these findings provide a proof-of-concept for the development of patient-derived PCC organoid models, which may ultimately serve as a platform for studying PCC biology and for future exploration of personalized therapeutic approaches.

Treatment with somatostatin, cortistatin, octreotide or pasireotide did not exert clear antitumoral effects on model cell lines...Molecular analysis revealed a generalized dephosphorylation affecting key proliferation, growth and cell survival pathways in response to BIM-23120 (unlike when treating with octreotide). Altogether, our results provide novel information on the status of the somatostatin system in PPGL and identify new potential therapeutic tools selectively targeting somatostatin receptors on this refractory tumor.